We really appreciate the comments of Salgado et al to our article. In our case, however, neither a specimen from the atypical proliferation in the congenital melanocytic nevus nor one from the metastasis showed amplification of n-ras. The software that we use to analyze comparative genomic hybridization results (Nexus 6.1; Biodiscovery, Hawthorne, CA) permits a “high power” view with a look up by gene. There is adequate probe coverage in the area of n-ras that amplification should be detectable. Regarding whether the congenital melanocytic nevus had an n-ras mutation, we attempted immunostaining with a new antibody that recognizes the codon 61R mutation (clone SP174, catalog number, M4742; Spring Bioscience, Pleasanton, CA), but the degree of background staining did not allow for a meaningful result. In the absence of amplification, given the frequency of n-ras mutations in large congenital nevi, we did not believe that the new knowledge acquired would justify the cost in performing Sanger sequencing for n-ras.Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.